In Q1 2017, Russia imported finished medicinal products worth 113.2 billion rubles (in prices set for release to free circulation), which is 8.7% more in ruble terms than in the same period of last year. In the first three months of 2017, the import of in-bulk medicinal products reached 20.6 billion rubles. Traditionally, the growth rates here are higher than for finished dosage forms. However, following quite low results in March, the overall quarterly growth for in-bulk products was fairly modest at 11.6%.
For finished dosage forms, the growth of physical volumes in January-March 2017 was also quite moderate. In this period, Russia imported about 470 million packages of foreign-made medicinal products, which is only 4.4% more than in the same period of last year. Moreover, this growth was only due to the change in the format of delivered packages. When recalculated in the minimum dosage units (MDU), the import of finished dosage forms shows a sharp drop (-9.8%), which so far is not even offset by increasing in-bulk deliveries, as the growth of the latter in MDU terms was slightly less than 12% over the year.
In Q1 2017, the leader in deliveries of finished dosage forms was Novartis, with the growth of 14% in ruble terms compared to the same period of last year. Sanofi ranked the second, but its deliveries have declined by 4%. Both companies are actively increasing in-bulk deliveries (by 2.6 and 4 times, respectively) and also supplying APIs to their own production facilities in St. Petersburg and Orel region.